Abstract for AD/PD™ 2026 Alzheimer’s & Parkinson’s Diseases Conference – March 17-21, 2026

AD/PD 2026 Intracerebroventricular administration of anaerobic dopamine in Parkinson’s disease patients refractory to L-dopa-based therapies Caroline Moreau, Véronique Foutel, Matthieu Fisichella, David Devos 1Parkinson’s Disease Centre of Excellence, Department of Neurology, University of Lille, CHU Lille, INSERM U1172—Treat, Lille, France. 2 InBrain Pharma, Lille, France. Objective To investigate the safety and efficacy of continuous circadian and personalized intracerebroventricular administration of anaerobic dopamine (A-dopamine) in Parkinson's disease patients refractory to L-dopa-based therapies. Methods A phase 1 study of A -dopamine titration with concomitant reduction of oral dopaminergic therapy was followed by a randomized, controlled, open -label, crossover phase 2 study comparing an A-dopamine treatment on top of a n optimized oral antiparkinsonian therapy to an optimized oral antiparkinsonian therapy alone over a month . Patients were then able to continue A-dopamine over the long term. The primary endpoints in phase I and in phase II were respectively safety and the blinded assessment of percentage over target (i.e., off and dyskinesia), recorded by actimetry at home using a wristwatch. Secondary endpoints included the fluctuations and dyskinesias on two -week home diaries, dyskinesia and MDS -UPDRS scales, safety and behavior using neuropsychological and psychiatric examinations. Results No serious adverse reactions induced by A-dopamine was observed in 12 patients. The primary criterion was significantly reduced on A-dopamine compared with oral treatment. The mean number of hours gained in the time to ‘on’ without dyskinesia was 4.4h (i.e. perfect control) and 6.6h of time with perfect versus control or slight off or slight dyskinesia with 60% reduction in the daily dose of oral antiparkinsonian drugs. All study p atients wanted to enter the long term follow up phase illustrating a sustainable therapy benefit, the absence of serious A-dopamine- or device-related adverse events over 4.5 years. Long-term safety is excellent, MRI monitoring didn’t reveal any structural changes. Conclusion These promising results will now be the subject of an international Phase III trial. Data showed a different effect of A-dopamine from that of L-dopa, notably with no A- dopamine-induced dyskinesia. Acknowledgment The study was funded by InBrain Pharma, France, a spin-off of the research academic team UMR-S 1172 (University of Lille, INSERM, University Hospital of Lille), which delegated the sponsorship of the study to the University Hospital of Lille, France.

The release as fetched from its publisher. inbrainpharma.com ↗